Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dexpramipexole

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

Biogen Idec building

Biogen elevates Vounatsos to top seat

US biotech’s CCO to succeed George Scangos on 6 January

Biogen Idec building

Biogen rises on more positive data for Alzheimer’s candidate

Early-stage trial throws lifeline to proponents of beleaguered amyloid hypothesis

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

PatientsLikeMe launches ‘virtual trial’ in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

- PMLiVE

Biogen launches Remicade biosimilar in the UK

Flixabi provides another low-cost alternative to J&J’s biggest-selling drug

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

Biogen promotes Dr Paul McKenzie

He becomes pharmaceutical operations and technology EVP

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links